Phase I
This year’s AACR Annual Meeting is coming to a close, and there has been a wealth of information and data presented. One topic of discussion stood out—mutations.
As the American Association of Cancer Research (AACR) Annual Meeting wraps up, there were some surprising and exciting research news and presentations.
Vertex has made a point over the past decade to make research and development a priority, investing over 70% of its expenses back into it.
Hundreds of presentations on oncology research are highlighted at the AACR Annual Meeting, which is running from April 7 to 13 in New Orleans.
Although the data was preliminary from a Phase Ib trial, investors are already speculating that the drug - when and if it makes it to regulators - could compete with Amgen’s Lumakras (sotorasib).
Cytovia could become the first company to use a combination of natural killer (NK) cells derived from induced pluripotent stem cell (iPSC) and NK engager antibodies to treat solid tumors.
Curis, a biotech company that develops treatments for cancer, has announced that the FDA has placed a partial clinical hold on its TakeAim lymphoma study.
The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans. Here’s a look at some of the preclinical and early-stage studies recently presented.
Shares fell in several life sciences companies at the close of the market Friday on apparently lackluster early data from their respective research projects. We look into each one below:
What if infants with genetic illnesses could be diagnosed in a matter of days? New research surrounding rapid whole genome sequencing suggests that soon, they could be.
PRESS RELEASES